Navigation Links
Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler
Date:6/8/2009

agen we lose over time with all-natural collagen. We are confident that the 12-month duration of EVOLENCE(R) positions it as a preferred choice within dermal filler options for both aesthetic health professionals and patients."

EVOLENCE(R) represents a breakthrough in aesthetics. As one of nature's most fundamental and abundant building blocks, collagen comprises up to 80 percent of the dermis and it helps maintain skin strength, structure and support. Collagen naturally breaks down as a person ages, leading to the appearance of wrinkles, lines and folds.

EVOLENCE(R), and its proprietary GLYMATRIX(TM) Technology, uses naturally sourced collagen to replace the body's lost collagen, adding volume and structural support in depleted areas, for a more naturally youthful appearance. In addition, no pre-test is needed, and GLYMATRIX(TM) Technology delivers longer-lasting durability than previous collagen dermal fillers.

Results are visible and immediate at the time of treatment, with minimal to no bruising or swelling, allowing physician and patient to gauge the amount of wrinkle correction with more precision.

About EVOLENCE(R):

EVOLENCE(R) is an advanced collagen-based structural dermal filler that provides long-lasting treatment of moderate to deep facial wrinkles and folds, such as nasolabial folds. The results of treatment with EVOLENCE(R) are immediate, with little to no downtime post-treatment and clinically proven to last through 12 months after initial treatment*.

Unlike other dermal fillers that use hyaluronic acid (HA), which absorb water to create their effect, EVOLENCE(R) is a true structural agent due to its three-dimensional collagen matrix. This collagen structure benefits patients as it is directly linked to the minimal bruising and swelling that might result. EVOLENCE(R) does not use chemicals for cross-linking like many o
'/>"/>

SOURCE Ortho Dermatologics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Photos: Breakthrough Technology Enables Edible TruTag(TM) to Prevent Counterfeit Medicine
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style
4. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
5. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
8. FDA Approves Label Change for Non-Invasive Fibroid Treatment
9. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
10. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
11. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... 18 /Xinhua-PRNewswire/ -- Today, NovaSecta,Sundia Meditech and ... drug discovery solutions for European pharmaceutical and ... quality scientific,capabilities of Sundia and HD BioSciences ... of European mid-sized pharmaceutical and,biotech companies., ...
... Much of the work in MIT Institute Professor Robert ... of science fiction, but its products are already saving lives ... of Langers specialties is growing the vital tissues of the ... such as the liver and intestinesin a laboratory dish instead ...
... Conn., Feb. 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... February 15, 2008 on its 7.75% Convertible Senior Notes,due ... Notes is $60,million., The Company paid $2,376,666.67 through ... $2,376,345.60 was paid in 5,500,800,shares of Common Stock, based ...
Cached Biology Technology:European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions 2European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions 3MIT researcher addresses biomedical engineering challenges 2MIT researcher addresses biomedical engineering challenges 3Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... the United States is in danger of coming to ... the requirement whether existing or anticipated to ... gas. But an MIT analysis suggests an intermediate step ... to fend off growing electricity shortages using our most-abundant, ...
... "chip" or array that can quickly detect disorders such as ... an effective tool in prenatal diagnosis in a series of ... a report that appears in the current issue of the ... team led by Dr. Arthur Beaudet and Dr. Sau Wai ...
... a relationship between two proteins in the brain that has ... led to speculation that existing drugs used to curb nicotine ... alleviate the symptoms of autism. The discovery identified a ... which is located in brain cells and assists in connecting ...
Cached Biology News:MIT: A quicker, easier way to make coal cleaner 2MIT: A quicker, easier way to make coal cleaner 3Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Researchers find link between nicotine addiction and autism 2Researchers find link between nicotine addiction and autism 3
... The Infinite 200 series of microplate ... or absorbance detection in an affordable, easy-to-use ... science applications. The unique modular design and ... researchers with a choice of a monochromator ...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: